ASX:SPL - DEP irinotecan combination outperforms in colon cancel model

Starpharma

Company

About Starpharma Leadership Our Brands Our Capabilities Research Publications ESG

DEP® Platform

Dendrimer Technology DEP® Drug Delivery Platform DEP® Solutions Our DEP® Pipeline

Partnerships

Partnering with Starpharma Star Navigator

Investors

Why Invest ASX Announcements Entitlement Offer News & Updates Investor Presentations Video Library Financial Reports Annual General Meeting 2025 Market Data Stock Listing Shareholder Services Corporate Governance

People & Culture

Our People & Culture Careers

DEP irinotecan combination outperforms in colon cancel model

Your question will be sent privately to Starpharma. The company may choose to make this question public.

Start the conversation

Ask Starpharma a question about this announcement.

Share your feedback

Discover